ALLO-715 vs Hrain anti-BCMA CAR-T

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

ALLO-715

Developed by Allogene Therapeutics, Inc.

Phase 1 in Multiple Myelomacell therapy (allogeneic anti-BCMA CAR-T)
Weak signal

NCT04093596 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715 (28 Days); To assess the overall safety profile and tolerability of ALLO-647 in combination with Fludarabine and/or cyclophosphamide or ALLO-647 alone, prior to ALLO-715 to confirm the dose of ALLO-647. (33 days); To assess the overall safety profile and tolerability of nirogacestat given concomitantly with ALLO-715 following lymphodepletion with Flu/ Cy/ ALLO-647. (28 days): UNIVERSAL phase 1 trial (NCT04093596, allogeneic anti-BCMA CAR T ALLO-715 in R/R multiple myeloma): ORR 55.8% across all 43 dosed patients; in the 24 patients at the optimal (DL3) dose plus ALLO-647 lymphodepletion, ORR 70.8% (45.8% VGPR+, 25% CR/sCR), median duration of response 8.3 months. (not_applicable)

Result source: NCT04093596

Hrain anti-BCMA CAR-T

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03093168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published five-year analysis reports 49 treated patients, more than this study's originally listed enrollment.

Reported efficacy

Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0 (6 months): ORR 77.55% (38/49 patients); sCR 24.49% (12 patients), CR 24.49% (12 patients); median PFS 9.5 months (95% CI 5.01-13.99), median OS 20.0 months (95% CI 11.26-28.74)

Result source: NCT03093168

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALLO-715Hrain anti-BCMA CAR-T
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

ALLO-715
—Not reported
Hrain anti-BCMA CAR-T
—Not reported

OS, median

ALLO-715
—Not reported
Hrain anti-BCMA CAR-T
—Not reported

ORR

ALLO-715
—Not reported
Hrain anti-BCMA CAR-T
—Not reported

VGPR or better

ALLO-715
—Not reported
Hrain anti-BCMA CAR-T
—Not reported

MRD negativity

ALLO-715
—Not reported
Hrain anti-BCMA CAR-T
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hrain anti-BCMA CAR-T: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ALLO-715
UNIVERSAL phase 1 trial (NCT04093596, allogeneic anti-BCMA CAR T ALLO-715 in R/R multiple myeloma): ORR 55.8% across all 43 dosed patients; in the 24 patients at the optimal (DL3) dose plus ALLO-647 lymphodepletion, ORR 70.8% (45.8% VGPR+, 25% CR/sCR), median duration of response 8.3 months. NCT04093596 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALLO-715's landscape · Hrain anti-BCMA CAR-T's landscape